Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Translation of Targeted Protein Degraders

3 Jul 2023

Abstract excerpt

Targeted protein degradation (TPD) has emerged as a potentially transformational therapeutic modality with considerable promise. Molecular glue degraders remodel the surface of E3 ligases inducing interactions with neosubstrates resulting in their polyubiquitination and proteasomal degradation. Molecular glues are clinically precedented and have demonstrated the ability to degrade proteins‐of‐interest (POIs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37399310
DOI: 10.1002/cpt.2985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Translation of Targeted Protein DegradersPMID 37399310Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for DegradersSemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Proteolysis‐targeting chimeras in drug development: A safety perspectiveSemantic proximity Read ↗

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical ApplicationsSemantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity Read ↗

Progress of small molecules for targeted protein degradation: PROTACs and other technologiesSemantic proximity Read ↗

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule InhibitorsSemantic proximity Read ↗

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.